The phase 2 ChonDRAgon study compared ozekibart to placebo in patients with metastatic or unresectable conventional chondrosarcoma who been diagnosed with radiographic progression.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback